Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Denali Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-03 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Denali Therapeutics Inc. shareholders approved Election of three Class III directors at the 2026-06-03 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
Election of three Class III directors to hold office until the 2029 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Denali Therapeutics Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-03 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
View on SEC.gov